Verrica Pharmaceuticals Inc.   Report issue

For profit Phase 3
Founded: West Chester PA United States (2013)

Organization Overview

First Clinical Trial
2017
NCT03186378
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Verrica Pharmaceuticals Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

cantharidin (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Condylomata Acuminata (Phase 2)

DNA Virus Infections (Phase 2)

Infections (Phase 2)

Molluscum Contagiosum (Phase 3)

Papillomavirus Infections (Phase 2)

Sexually Transmitted Diseases (Phase 2)

Sexually Transmitted Diseases, Viral (Phase 2)

Skin Diseases (Phase 2)

Skin Diseases, Infectious (Phase 2)

Skin Diseases, Viral (Phase 2)

Tumor Virus Infections (Phase 2)

Virus Diseases (Phase 2)

Warts (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 1